Report about four novel mutations in the prion protein gene.

Dement Geriatr Cogn Disord

Department of Neurology, Clinical Dementia Center, Georg August University Goettingen, Goettingen, Germany. epicjd @ med.uni-goettingen.de

Published: October 2013

Background/aims: Since detection of the prion protein gene (PRNP) more than 30 mutations have been discovered. Some have only been found in single case reports without known intrafamilial accumulation or neuropathological proof so that the causal connection between mutation and disease could not be proved. Those patients often present atypical clinical phenotypes, and it is not unusual that they are classified as diseases other than Creutzfeldt-Jakob disease (CJD).

Methods: Cases of suspected CJD have been reported to the national reference center for prion diseases. Clinical and diagnostic data were collected, and a classification of definite, possible or probable prion disease was made. Molecular analysis of PRNP was performed by capillary sequencing.

Results: We have described 4 cases with atypical clinical and diagnostic findings and unknown mutations in PRNP so far.

Conclusion: Three patients fulfilled the criteria of probable CJD, and 1 patient fulfilled the criteria of possible CJD but the clinical picture in none of the patients was typical CJD; hence, it remained questionable whether the mutations were causal of the disease.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000345991DOI Listing

Publication Analysis

Top Keywords

prion protein
8
protein gene
8
atypical clinical
8
clinical diagnostic
8
fulfilled criteria
8
report novel
4
mutations
4
novel mutations
4
prion
4
mutations prion
4

Similar Publications

Background: Abnormal protein depositions of amyloid β and tau are present in the nasal cavity in patients with Alzheimer's disease. This finding raises an idea that nasal tissues would be a promising source of diagnostic biomarkers for Alzheimer's disease. However, the amounts of amyloid β and tau are extremely small, making it difficult to quantify the levels using conventional methods such as ELISA, and thus it is challenging to utilize them for the diagnostic biomarkers.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Orsay, France.

Background: Typical Alzheimer's disease (AD) and Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) are two neurodegenerative diseases that present with a similar initial amnestic clinical phenotype but have distinct proteinopathies. AD is characterised by ß-amyloid plaques and intraneuronal neurofibrillary tangles, while LATE is characterised by abnormal neuronal TDP-43 protein. With reference to the prion-like hypothesis regarding the propagation of proteinopathies, investigating white matter fibre bundle alterations could provide new insights into the propagation pathways of specific proteinopathies.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is an heterogenous disorder characterized by the accumulation of amyloid-beta (Aβ) and tau. One possible explanation for the clinical and pathological variation in AD lies in the presence of distinct conformational strains of Aβ. Numerous studies provide compelling evidence for the existence of such strains as well as their ability to template their conformations in a prion-like manner.

View Article and Find Full Text PDF

Background: Regional distribution of neurofibrillary tangles consisting of hyperphosphorylated tau correlates strongly with the progression of Alzheimer's disease (AD). Misfolded proteopathic tau templates the conversion of naive tau into a pathological state in a prion-like fashion, which underlies the spreading of tau pathology in the brain. Whether hyperphosphorylation triggers tau aggregation or hyperphosphorylation occurs after aggregation is under much debate.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

ADEL Institute of Science & Technology (AIST), ADEL, Inc., Seoul, Korea, Republic of (South).

Background: The spatiotemporal pattern of the spread of pathologically modified tau through brain regions in Alzheimer's disease (AD) can be explained by prion-like cell-to-cell seeding and propagation of misfolded tau aggregates. Hence, to develop targeted therapeutic antibodies, it is important to identify the seeding- and propagation-competent tau species. The hexapeptide VQIINK of tau is a critical region for tau aggregation, and K280 is acetylated in various tauopathies including AD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!